2025

Imaging BiTE-Mediated Activation of Primary Human CD8+ T Cells
Winterberg K, Möller C, Schwarze L, Cichutek S, Hambach J, Guse A, Fehse B, Diercks B, Riecken K
Methods Mol Biol. 2025;2904:159-177.

2024

BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report
Cords L, Schaefers C, Kamili A, Hoffmann C, Cichutek S, Haag F, Polywka S, Bokemeyer C, Leypoldt L, Alsdorf W, Schulze zur Wiesch J, Weisel K
HAEMATOLOGICA. 2024;109(9):3071-3077.

Dose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML)
Schönrock M, Sonnemann P, Michalowski N, Heuser M, Thol F, Ayuk F, Wolschke C, Klyuchnikov E, Bokemeyer C, Fiedler W, Cichutek S
CANCERS. 2024;16(22):.

2023

Broadening the horizon: potential applications of CAR-T cells beyond current indications
Karsten H, Matrisch L, Cichutek S, Fiedler W, Alsdorf W, Block A
FRONT IMMUNOL. 2023;14:1285406.

2020

Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
Hambach J, Riecken K, Cichutek S, Schütze K, Albrecht B, Petry K, Röckendorf J, Baum N, Kröger N, Hansen T, Schuch G, Haag F, Adam G, Fehse B, Bannas P, Koch-Nolte F
CELLS-BASEL. 2020;9(2):.

Letzte Aktualisierung aus dem FIS: 28.08.2025 - 05:17 Uhr